Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -143.82% is 77% below its 5-year average of -81.19%, near the low end of its 5-year range (-151.68%–-18.90%).
2.63% below its 12-month average of -140.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -36.21%.
RETURN ON ASSETS (ROA)
-143.82%
RETURN ON ASSETS (ROA) AVG TTM
-140.13%
RETURN ON ASSETS (ROA) AVG 3Y
-102.17%
RETURN ON ASSETS (ROA) AVG 5Y
-81.19%
RETURN ON ASSETS (ROA) AVG 10Y
-303.49%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.63%
CURRENT VS 3Y AVG
-40.76%
CURRENT VS 5Y AVG
-77.15%
CURRENT VS 10Y AVG
+52.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.29%
median of 679 covered companies
CURRENT VS SECTOR MEDIAN
-374.81%
vs the sector median at left
Moleculin Biotech, Inc.
Market Cap
$2.47M
Return on Assets (ROA)
-143.82%
TTM Avg
-140.13%
3Y Avg
-102.17%
5Y Avg
-81.19%
Market Cap
$2.56M
Return on Assets (ROA)
-107.18%
TTM Avg
-105.74%
3Y Avg
-98.21%
5Y Avg
-95.08%
Market Cap
$2.61M
Return on Assets (ROA)
-121.85%
TTM Avg
-199.78%
3Y Avg
-166.32%
5Y Avg
-134.78%
Market Cap
$2.58M
Return on Assets (ROA)
-199.30%
TTM Avg
-137.41%
3Y Avg
-109.57%
5Y Avg
-977.62%
Market Cap
$2.58M
Return on Assets (ROA)
-228.77%
TTM Avg
-130.86%
3Y Avg
-126.84%
5Y Avg
-140.90%
Market Cap
$2.32M
Return on Assets (ROA)
-64.42%
TTM Avg
-79.57%
3Y Avg
-65.34%
5Y Avg
-858.61%
Market Cap
$2.64M
Return on Assets (ROA)
-154.47%
TTM Avg
-121.84%
3Y Avg
-88.87%
5Y Avg
-75.91%
Market Cap
$2.33M
Return on Assets (ROA)
-62.07%
TTM Avg
-132.28%
3Y Avg
-89.58%
5Y Avg
-83.72%
Market Cap
$2.27M
Return on Assets (ROA)
-439.95%
TTM Avg
-322.44%
3Y Avg
-242.34%
5Y Avg
-192.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.47M | -143.82% | -140.13% | -102.17% | -81.19% |
| Jaguar Health, Inc. (JAGX)vs › | $2.56M | -107.18% | -105.74% | -98.21% | -95.08% |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | -121.85% | -199.78% | -166.32% | -134.78% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.58M | -199.30% | -137.41% | -109.57% | -977.62% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.58M | -228.77% | -130.86% | -126.84% | -140.90% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -64.42% | -79.57% | -65.34% | -858.61% |
| iSpecimen Inc. (ISPC)vs › | $2.64M | -154.47% | -121.84% | -88.87% | -75.91% |
| Onconetix, Inc. (ONCO)vs › | $2.33M | -62.07% | -132.28% | -89.58% | -83.72% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.27M | -439.95% | -322.44% | -242.34% | -192.54% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.94M | -404.67% | -168.15% | -182.58% | -275.93% |
ROA
-143.8%
ROE
-261.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -151.68% |
| 2024-12-31 | -128.58% |
| 2023-12-31 | -77.89% |
| 2022-12-31 | -50.55% |
| 2021-12-31 | -18.90% |
| 2020-12-31 | -59.52% |
| 2019-12-31 | -52.33% |
| 2018-12-31 | -60.64% |
| 2017-12-31 | -50.33% |
| 2016-12-31 | -23.95% |
| 2015-12-31 | -2664.06% |
